LOGO
LOGO

Travere Therapeutics Secures Key FDA Approval, Stock Climbs

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024

Shares of Travere Therapeutics Inc. (TVTX) were up over 8% at $10.25 in after-hours trading Thursday, following favorable regulatory news.

The FDA has granted full approval to Filspari to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression.

IgA nephropathy, also known as Berger's disease, is a rare progressive kidney disease. It occurs when a protein called immunoglobulin A (IgA), which normally helps fight infections, builds up in the kidneys. This buildup affects the normal filtering mechanisms in the kidney, leading to blood in the urine (hematuria), protein in the urine (proteinuria), and a progressive loss of kidney function over time.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update -May 18 – May 22, 2026

May 22, 2026 14:46 ET
Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.

Latest Updates on COVID-19